Here's some of what is coming soon to NeurologyLive® this week.
|Articles|December 31, 2019
NeurologyLive Year in Review: Top FDA Approvals
Author(s)Alicia Bigica
The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments for Parkinson disease and epilepsy.
Advertisement
US Food and Drug Administration
2019 has been a monumental year for new therapies for neurologic diseases. From migraine to MS, the FDA has approved numerous new treatments to address unmet needs in a range of disorders, including the first ever gene therapy for spinal muscular atrophy, as well as the first drug approved for episodic cluster headache.
The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments and improve time to treatment effect in conditions like Parkinson disease and epilepsy.
Look back on some of the most signficant FDA approvals in 2019 through the links below:
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
Here's some of what is coming soon to NeurologyLive® this week.
The clinical professor of neurology and pediatrics at The Ohio State University Wexner Medical Center discussed payer step therapy, earlier preventive treatment, and questions the updated guideline leaves open.
Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.
Paul Melmeyer, MPP, Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association, discusses the Neuromuscular Advocacy Collaborative, its growing year-round presence, and what the group hopes to accomplish heading into the 2027 MDA Clinical and Scientific Conference.
Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.
The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Blood-Based Biomarkers for Monitoring Treatment Response in Multiple Sclerosis
2
Machine Learning Spots Early Signs of MS and NMOSD Years in Advance
3
Incorporating the Updated AAN/AHS Migraine Prevention Guideline Into Practice
4
Advancing Biomarkers for Cerebral Small Vessel Disease Trials: Joanna Wardlaw, MD
5